Albany Molecular Research EBIT

Albany Molecular Research (AMRI) currently reports a EBIT of $-17M as of June 2017. That compares with $3M in the prior-year period — down 673.9% year over year. That is below the sector sector average of $2.5T. Use the charts on this page to explore Albany Molecular Research's EBIT history and peer comparisons.

Albany Molecular Research's EBIT decreased from $3M to $-17M — a 673.9% year-over-year decrease (period ending June 2017). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Albany Molecular Research's EBIT of $-17M is lower than the its sector sector average of $2.5T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Albany Molecular Research reported $-17M in EBIT as of June 2017. That compares with $3M in the prior-year period — down 673.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-17M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.5T. From there, open related valuation or income-statement pages for Albany Molecular Research, and consider following AMRI for alerts when major investors trade the stock.